PRTA Key Statistics, Chart & Performance
The current stock price of PRTA is 9.19 USD. In the past month the price decreased by -6.89%. In the past year, price decreased by -29.58%.
PRTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About PRTA
Company Profile
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Company Info
PROTHENA CORP PLC
77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60 IE
CEO: Gene G. Kinney
Employees: 163
Phone: 35312362500
PROTHENA CORP PLC / PRTA FAQ
What does PROTHENA CORP PLC do?
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
What is the current price of PRTA stock?
The current stock price of PRTA is 9.19 USD. The price increased by 1.55% in the last trading session.
Does PRTA stock pay dividends?
PRTA does not pay a dividend.
How is the ChartMill rating for PROTHENA CORP PLC?
PRTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists PRTA stock?
PRTA stock is listed on the Nasdaq exchange.
How is the market expecting PRTA stock to perform?
13 analysts have analysed PRTA and the average price target is 20.74 USD. This implies a price increase of 125.68% is expected in the next year compared to the current price of 9.19.
Can you provide the number of employees for PROTHENA CORP PLC?
PROTHENA CORP PLC (PRTA) currently has 163 employees.
PRTA Technical Analysis
PRTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRTA. While PRTA has a great health rating, there are worries on its profitability.
PRTA Financial Highlights
Over the last trailing twelve months PRTA reported a non-GAAP Earnings per Share(EPS) of -4.61. The EPS decreased by -85.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.53% | ||
| ROE | -95.07% | ||
| Debt/Equity | 0 |
PRTA Forecast & Estimates
13 analysts have analysed PRTA and the average price target is 20.74 USD. This implies a price increase of 125.68% is expected in the next year compared to the current price of 9.19.
For the next year, analysts expect an EPS growth of -109.62% and a revenue growth -92.13% for PRTA